Elevated serum interferon-gamma-inducible chemokine-10/CXC chemokine ligand-10 in autoimmune primary adrenal insufficiency and in vitro expression in human adrenal cells primary cultures after stimulation with proinflammatory cytokines.

Chemokines are a large family of cytokines involved in the pathogenesis of inflammatory and autoimmune diseases. Among CXC chemokines, CXC chemokine ligand 10 (CXCL10) has been identified to play an important role in several endocrinological autoimmune diseases, such as Hashimoto's thyroiditis, Graves' disease, and type 1 diabetes mellitus. Although the mechanisms leading to glandular autoimmune process may be at least in part shared by different endocrine organs, the role of CXCL10 in autoimmune adrenal insufficiency is unknown. The aim of this study was to evaluate the role of CXCL10 in Addison's disease (AD). Serum CXCL10 levels were assayed in 64 patients with clinically evident autoimmune AD, 20 patients with autoimmune subclinical AD, nine patients with nonautoimmune AD, and 48 healthy volunteers. Clinically evident and subclinical AD, but not nonautoimmune AD patients, showed a significant increase in serum CXCL10 levels compared with healthy subjects: 119.9 pg/ml (range, 39.8-427.6) and 124.0 pg/ml (range, 37.0-384.7) vs. 75.6 pg/ml (range, 22.4-164.0; P < 0.001 for both groups). Comparable serum CXCL10 levels were found between patients with an isolated form of AD and patients with other autoimmune conditions associated with AD, suggesting a specific influence of the adrenal autoimmune process in determining elevated CXCL10 concentrations in such patients. No relationship was found between serum CXCL10 levels and anti-21-hydroxylase or adrenal cortex autoantibody titers or between CXCL10 levels and duration of disease. The role of CXCL10 in the adrenal gland was also evaluated in vitro in human zona fasciculata cells (hZFC). CXCL10, although not basally detected in cultured hZFC, was strongly induced by interferon-gamma and synergistically increased by TNF-alpha addition. Hydrocortisone or ACTH alone had no effect on CXCL10 secretion in hZFC, but they both significantly inhibited cytokine-induced CXCL10 secretion. Taken together, these data suggest a potential role of hZFC, through the production of CXCL10, in regulating the recruitment of specific subsets of activated lymphocytes in autoimmune AD.

[1]  M. Rotondi,et al.  High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism. , 2004, The Journal of clinical endocrinology and metabolism.

[2]  G. Arnaldi,et al.  Italian addison network study: update of diagnostic criteria for the etiological classification of primary adrenal insufficiency. , 2004, The Journal of clinical endocrinology and metabolism.

[3]  Gabriella Nesi,et al.  Expression of the novel adrenocorticotropin-responsive gene selective Alzheimer's disease indicator-1 in the normal adrenal cortex and in adrenocortical adenomas and carcinomas. , 2004, The Journal of clinical endocrinology and metabolism.

[4]  S. Bornstein,et al.  Cytokines and steroidogenesis , 2004, Molecular and Cellular Endocrinology.

[5]  A. Weetman,et al.  Detection and localization of chemokine gene expression in autoimmune thyroid disease , 2003, Clinical endocrinology.

[6]  M. Rotondi,et al.  —to: Nicoletti F, Conget L, Di Mauro M et al. (2002) Serum concentrations of the interferon-α-inducible chemokine IP-10/CXCL10 are augmented in both newly-diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease. Diabetologia 45:1107–1110 , 2003, Diabetologia.

[7]  L. Ivashkiv,et al.  Inhibition of IFN-γ Signaling by Glucocorticoids1 , 2003, The Journal of Immunology.

[8]  M. Rotondi,et al.  Role for interferon-γ inducible chemokines in endocrine autoimmunity: An expanding field , 2003 .

[9]  F. Nicoletti,et al.  Serum concentrations of the interferon-γ-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease , 2002, Diabetologia.

[10]  Luca Chiovato,et al.  Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves' disease. , 2002, The American journal of pathology.

[11]  F. Mantero,et al.  Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. , 2002, Endocrine reviews.

[12]  E. Husebye,et al.  Autoimmune adrenocortical failure in Norway autoantibodies and human leukocyte antigen class II associations related to clinical features. , 2002, The Journal of clinical endocrinology and metabolism.

[13]  F. Sánchez‐Madrid,et al.  Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3+ lymphocytes. , 2001, The Journal of clinical endocrinology and metabolism.

[14]  T. Giordano,et al.  Overexpression of CXC chemokines by an adrenocortical carcinoma: a novel clinical syndrome. , 2001, The Journal of clinical endocrinology and metabolism.

[15]  Maria I. New,et al.  Addison’s Disease 2001 , 2001 .

[16]  R. Bergamaschi,et al.  Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies , 2001, Journal of Neuroimmunology.

[17]  T. Mcclanahan,et al.  Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.

[18]  Y Oikawa,et al.  Elevated serum IP-10 levels observed in type 1 diabetes. , 2001, Diabetes care.

[19]  T. Okanoue,et al.  Increase of chemokine interferon‐inducible protein‐10 (IP‐10) in the serum of patients with autoimmune liver diseases and increase of its mRNA expression in hepatocytes , 2001, Clinical and experimental immunology.

[20]  T. Takeuchi,et al.  Serum levels of ifn-inducible PROTEIN-10 relating to the activity of systemic lupus erythematosus. , 2000, Cytokine.

[21]  R. Uibo,et al.  Adrenal Autoimmunity: Results and Developments , 2000, Trends in Endocrinology & Metabolism.

[22]  E. Arvat,et al.  Low dose (1 μg) ACTH test in the evaluation of adrenal dysfunction in pre‐clinical Addison's disease , 2000, Clinical endocrinology.

[23]  P. Brunetti,et al.  Increased risk for endocrine autoimmunity in Italian type 2 diabetic patients with GAD65 autoantibodies , 2000, Clinical endocrinology.

[24]  D. Franchimont,et al.  Inhibition of Th1 Immune Response by Glucocorticoids: Dexamethasone Selectively Inhibits IL-12-Induced Stat4 Phosphorylation in T Lymphocytes1 , 2000, The Journal of Immunology.

[25]  A. Zlotnik,et al.  Chemokines: a new classification system and their role in immunity. , 2000, Immunity.

[26]  F. Santeusanio,et al.  Is the prevalence of Addison's disease underestimated? , 1999, The Journal of clinical endocrinology and metabolism.

[27]  F. Santeusanio,et al.  Levels of adrenocortical autoantibodies correlate with the degree of adrenal dysfunction in subjects with preclinical Addison's disease. , 1998, The Journal of clinical endocrinology and metabolism.

[28]  M. Karin New Twists in Gene Regulation by Glucocorticoid Receptor: Is DNA Binding Dispensable? , 1998, Cell.

[29]  R. Strieter,et al.  The role of CXC chemokines in the regulation of angiogenesis in non‐small cell lung cancer , 1997, Journal of leukocyte biology.

[30]  S J Gange,et al.  Epidemiology and estimated population burden of selected autoimmune diseases in the United States. , 1997, Clinical immunology and immunopathology.

[31]  B. Rousset,et al.  Gap junction-mediated cell-to-cell communication in bovine and human adrenal cells. A process whereby cells increase their responsiveness to physiological corticotropin concentrations. , 1995, The Journal of clinical investigation.

[32]  W. Scherbaum,et al.  Macrophages within the human adrenal gland , 1994, Cell and Tissue Research.

[33]  D. Boumpas,et al.  Glucocorticoid Therapy for Immune-Mediated Diseases: Basic and Clinical Correlates , 1993, Annals of Internal Medicine.

[34]  A. Weetman,et al.  Adrenocorticotropic hormone receptor-blocking immunoglobulins in serum from patients with Addison's disease: a reexamination. , 1993, The Journal of clinical endocrinology and metabolism.

[35]  A. Bellastella,et al.  Remission of subclinical adrenocortical failure in subjects with adrenal autoantibodies. , 1993, The Journal of clinical endocrinology and metabolism.

[36]  A. Weetman,et al.  T and B cell reactivity to adrenal antigens in autoimmune Addison's disease , 1992, Clinical and experimental immunology.

[37]  T. Yokochi,et al.  Experimental autoimmune adrenalitis: a murine model for Addison's disease. , 1992, Autoimmunity.